Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05586321 | Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors | PHASE1 | COMPLETED | 26 | — | — | Oct 1, 2022 | Oct 1, 2025 | Nov 23, 2025 | - | — |
| Name | Type | Description |
|---|---|---|
| GEN1056 | BIOLOGICAL | GEN1056 will be administered as an intravenous (IV) infusion. The dose levels will be determined by the starting dose and the escalation steps taken in the trial in Part 1. In Part 2, the dose and schedule will be decided based on data outcome from Part 1. |